Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prophylaxis for HIV-associated infections in the developing world

C F Gilks1

  • 1Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, UK.

The Journal of Antimicrobial Chemotherapy
|February 1, 1993
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.

The Journal of antimicrobial chemotherapy·2014
Same author

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

Antimicrobial agents and chemotherapy·2010
Same author

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.

Lancet (London, England)·2010
Same author

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

HIV medicine·2010
Same author

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Lancet (London, England)·2009
Same author

Management of HIV-infected patients with MDR- and XDR-TB in resource-limited settings.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2008

Prophylaxis for HIV-associated infections like pneumococcal disease, tuberculosis, and salmonellosis is crucial in developing nations. Implementing cost-effective preventive strategies, including vaccines, can significantly improve survival and quality of life for HIV patients.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Tropical Medicine

Background:

  • HIV-associated infections significantly impact survival and quality of life in industrialized nations due to prophylaxis.
  • The HIV epidemic is rapidly expanding in developing countries where prophylaxis is not utilized or recommended.
  • Key pathogens in the tropics include Streptococcus pneumoniae, Mycobacterium tuberculosis, and non-typhi salmonellae.

Purpose of the Study:

  • To evaluate the potential cost-effectiveness of prophylaxis for specific HIV-associated infections in developing countries.
  • To highlight the need for preventive strategies against common tropical pathogens in HIV-infected populations.
  • To discuss the challenges and potential benefits of implementing chemoprophylaxis and immunization programs.

Main Methods:

Keywords:
Antibiotics--administraction and dosageBacterial And Fungal Diseases--prevention and controlDelivery Of Health CareDeveloping CountriesDiseasesDrugsHealthHealth ServicesHiv InfectionsImmunizationInfectionsMedicinePreventive MedicinePrimary Health CareTreatmentTuberculosis--prevention and controlVaccinationViral Diseases

Related Experiment Videos

  • Review of existing literature on HIV-associated infections and prophylaxis efficacy in tropical regions.
  • Discussion of potential intervention strategies, including chemoprophylaxis and vaccination.
  • Analysis of cost-benefit considerations for implementing preventive measures.

Main Results:

  • Prophylaxis for infections like pneumococcal disease, tuberculosis, and salmonellosis may be cost-effective in the tropics, improving productive life years.
  • Prevention of pneumococcal disease has been overlooked, with penicillin chemoprophylaxis and immunization as potential interventions.
  • HIV-associated tuberculosis requires further study, with compliance being a major operational challenge for chemoprophylaxis.
  • Systemic salmonellosis, a leading cause of death, may be managed with costly chemoprophylaxis, while novel vaccines offer future promise.

Conclusions:

  • Implementing prophylaxis for Streptococcus pneumoniae, Mycobacterium tuberculosis, and non-typhi salmonellae in HIV-infected individuals in the tropics is essential.
  • Further research is needed to assess the efficacy, cost-effectiveness, and operational feasibility of various preventive strategies.
  • Vaccination, particularly with novel or unlicensed vaccines, may offer the most effective long-term solution for controlling these infections.